Insider Transactions in Q1 2024 at Entrada Therapeutics, Inc. (TRDA)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
1,512
+2.44%
|
$19,656
$13.75 P/Share
|
|
Mar 26
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
2,750
+4.47%
|
$35,750
$13.64 P/Share
|
|
Mar 25
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
3,180
+5.37%
|
$41,340
$13.36 P/Share
|
|
Mar 22
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
3,118
+5.57%
|
$40,534
$13.76 P/Share
|
|
Mar 21
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
704
+1.39%
|
$9,152
$13.24 P/Share
|
|
Mar 20
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
1,128
+2.25%
|
$13,536
$12.66 P/Share
|
|
Mar 19
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
900
+1.84%
|
$10,800
$12.66 P/Share
|
|
Mar 15
2024
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+9.76%
|
$18,000
$2.1 P/Share
|
|
Mar 06
2024
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,086
-5.22%
|
$49,032
$12.31 P/Share
|
|
Mar 06
2024
|
Nathan J Dowden President & COO |
SELL
Open market or private sale
|
Direct |
1,826
-1.31%
|
$21,912
$12.32 P/Share
|
|
Mar 05
2024
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,505
-0.71%
|
$18,060
$12.28 P/Share
|
|
Mar 05
2024
|
Nathan J Dowden President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,486
-1.06%
|
$17,832
$12.28 P/Share
|
|
Mar 05
2024
|
Kory James Wentworth Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,471
-1.85%
|
$17,652
$12.28 P/Share
|
|
Mar 05
2024
|
Dipal Doshi CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,049
-1.46%
|
$60,588
$12.28 P/Share
|
|
Mar 04
2024
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Payment of exercise price or tax liability
|
Direct |
761
-0.18%
|
$9,132
$12.9 P/Share
|
|
Mar 04
2024
|
Nathan J Dowden President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
752
-0.27%
|
$9,024
$12.9 P/Share
|
|
Mar 04
2024
|
Kory James Wentworth Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
744
-0.46%
|
$8,928
$12.9 P/Share
|
|
Mar 04
2024
|
Dipal Doshi CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,555
-0.37%
|
$30,660
$12.9 P/Share
|
|
Mar 01
2024
|
Natarajan Sethuraman President, Research & Develop. |
BUY
Grant, award, or other acquisition
|
Direct |
44,100
+17.27%
|
-
|
|
Mar 01
2024
|
Nathan J Dowden President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
93,100
+29.38%
|
-
|
|
Mar 01
2024
|
Kory James Wentworth Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,900
+27.75%
|
-
|
|
Mar 01
2024
|
Dipal Doshi CEO |
BUY
Grant, award, or other acquisition
|
Direct |
104,700
+23.13%
|
-
|
|
Feb 15
2024
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
1,000
-0.41%
|
$15,000
$15.0 P/Share
|
|
Jan 16
2024
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
1,000
-0.41%
|
$15,000
$15.99 P/Share
|